Edition:
India

Zur Rose Group AG (ROSEG.S)

ROSEG.S on Swiss Exchange

278.00CHF
6:56pm IST
Change (% chg)

CHF1.00 (+0.36%)
Prev Close
CHF277.00
Open
CHF277.00
Day's High
CHF281.50
Day's Low
CHF271.50
Volume
25,838
Avg. Vol
107,177
52-wk High
CHF304.50
52-wk Low
CHF93.20

Latest Key Developments (Source: Significant Developments)

Zur Rose Q3 Revenue Up At CHF 435.3 Million
Wednesday, 21 Oct 2020 

Oct 21 (Reuters) - ZUR ROSE GROUP AG ::ACCELERATES GROWTH IN THIRD QUARTER 2020.REVENUE GROWTH OF 15.3 PER CENT IN Q3 AND CONSIDERABLE INCREASE QUARTER-ON-QUARTER.FULL YEAR OUTLOOK CONFIRMED.IN Q3 OF 2020 ZUR ROSE GROUP GENERATED REVENUE OF CHF 435.3 MILLION (INCLUDING MEDPEX AND APOTAL), EQUIVALENT TO A SIGNIFICANT 15.3 PER CENT RISE IN LOCAL CURRENCY TERMS.  Full Article

EU Commission OKs German Plan To Ban Discounts By Mail-Order Pharmacies - Handelsblatt
Tuesday, 6 Oct 2020 

Oct 6 (Reuters) - Handelsblatt::EU COMMISSION APPROVES GERMAN PLAN TO BAN DISCOUNTS BY MAIL-ORDER PHARMACIES.  Full Article

Zur Rose Group And KPT Launch Digital Medicines Assistant Medi+
Tuesday, 8 Sep 2020 

Sept 8 (Reuters) - Zur Rose Group AG ::ZUR ROSE GROUP AG - ZUR ROSE AND KPT TOGETHER LAUNCH DIGITAL MEDICINES ASSISTANT MEDI+.  Full Article

Zur Rose Group Says Public Prosecutor Of Canton Charges Files Charges Against CEO In Connection With Mail-Order Of Non-Prescription Drugs & Electronic Prescribing
Sunday, 3 May 2020 

May 3 (Reuters) - Zur Rose Group AG ::EQS-NEWS: ZUR ROSE GROUP: CHARGES IN CONNECTION WITH MAIL-ORDER OF NON-PRESCRIPTION DRUGS AND ELECTRONIC PRESCRIBING.ZUR ROSE GROUP- PUBLIC PROSECUTOR OF CANTON OF THURGAU FILES CHARGES AGAINST CEO WALTER OBERHÄNSLI IN CONNECTION WITH MAIL-ORDER OF NON-PRESCRIPTION DRUGS & ELECTRONIC PRESCRIBING.ZUR ROSE GROUP AG - KREUZLINGEN PUBLIC PROSECUTOR FILED CHARGES AGAINST WALTER OBERHÄNSLI IN HIS CAPACITY AS CEO OF ZUR ROSE GROUP.ZUR ROSE GROUP AG - CHARGES ARE BASED ON A REPORT OF A CRIMINAL OFFENCE LODGED BY PHARMASUISSE.ZUR ROSE-CHARGES RELATE TO 2 SEPARATE ISSUES: MAIL-ORDER DISTRIBUTION OF NON-PRESCRIPTION DRUGS &REWARDING DOCTORS FOR ISSUING ELECTRONIC PRESCRIPTIONS BETWEEN 2010&2015.ZUR ROSE GROUP AG - BOARD REJECTS ACCUSATIONS MADE AGAINST CEO & ANNOUNCES SUPPORT TO WALTER OBERHÄNSLI "UNRESERVEDLY" IN FIGHTING CHARGES.ZUR ROSE GROUP AG - RULES OUT AN IMPACT OF PROCEEDINGS ON CURRENT BUSINESS PERFORMANCE.  Full Article

Zur Rose FY Revenue Up 30.1% To CHF 1.57 Billion
Wednesday, 22 Jan 2020 

Jan 22 (Reuters) - Zur Rose Group Ag ::EQS-NEWS: ZUR ROSE GROUP POSTS 30 PER CENT GROWTH IN 2019.EBITDA TARGETS FOR 2019 CONFIRMED.GROWTH TARGETS SUCCESSFULLY IMPLEMENTED IN 2019.FY REVENUE GROWTH OF 30.1 PER CENT TO CHF 1,570.1 MILLION.CONFIRMS PROFIT FORECAST FOR 2019.CONFIRMS OUTLOOK FOR 2022, WITH MANAGEMENT LOOKING TO DOUBLE REVENUE GENERATED IN 2018 WITH A TARGET EBITDA MARGIN OF 5 TO 6 PER CENT.  Full Article

Zur Rose Group: Purchase Price Payment For Medpex Acquisition Completed Early
Friday, 27 Dec 2019 

Dec 27 (Reuters) - Zur Rose Group AG ::PURCHASE PRICE PAYMENT FOR MEDPEX ACQUISITION COMPLETED EARLY BY EARN-OUT SETTLEMENT.ONE-OFF PAYMENT OF AMOUNT ESTIMATED IN 2019 INTERIM FINANCIAL STATEMENTS.  Full Article

Zur Rose Group H1 Net Loss Of CHF 17.1 Mln
Wednesday, 21 Aug 2019 

Aug 21 (Reuters) - Zur Rose Group Ag ::CONFIRMS REVENUE OUTLOOK ANNOUNCED FOR FULL YEAR 2019.TARGETS FOR 2022 CONFIRMED.INCLUDING MEDPEX SALES, H1 GROUP REVENUE WAS UP 28.1 PER CENT TO CHF 771.8 MILLION YEAR ON YEAR.H1 EBITDA MARGIN IMPROVED FROM MINUS 1.5 PER CENT TO MINUS 0.4 PER CENT.INCLUDING ALL EXCEPTIONAL ITEMS, H1 EBITDA IMPROVED FROM MINUS CHF 9.0 MILLION TO MINUS CHF 2.5 MILLION.H1 NET INCOME / (LOSS) OF MINUS CHF 17.1 MILLION WAS INCURRED (PREVIOUS YEAR: MINUS CHF 17.6 MILLION).  Full Article

Zur Rose Group Q1 Revenue Up 28.1 Pct At CHF 381.1 Mln
Wednesday, 17 Apr 2019 

April 17 (Reuters) - Zur Rose Group AG ::EQS-NEWS: ZUR ROSE GROUP GROWS 28 PER CENT IN THE FIRST QUARTER OF 2019.REVENUE FORECAST FOR YEAR AS A WHOLE REAFFIRMED.INCREASE IN REVENUE OF 28.1 PER CENT TO CHF 381.1 MILLION IN Q1.IT WAS NOT POSSIBLE TO CONSOLIDATE MEDPEX REVENUE AS OF YET IN Q1 OF 2019.REAFFIRMS AIM OF ACHIEVING BREAK-EVEN AT EBITDA LEVEL IN 2019.  Full Article

Zur Rose Group Nominates Three New Board Members
Monday, 15 Apr 2019 

April 15 (Reuters) - ZUR ROSE GROUP AG ::NOMINATES THREE NEW BOARD MEMBERS.NOMINATES TOBIAS HARTMANN, DR. CHRISTIAN MIELSCH AND FLORIAN SEUBERT AS NEW MEMBERS OF BOARD OF DIRECTORS.  Full Article

Zur Rose Group: Vanessa Frey And Heinz O. Baumgartner Not To Stand For Re-Election
Monday, 4 Mar 2019 

March 4 (Reuters) - Zur Rose Group AG ::EQS-NEWS: CHANGE ON THE BOARD OF DIRECTORS OF THE ZUR ROSE GROUP.ZUR ROSE GROUP - VANESSA FREY AND HEINZ O. BAUMGARTNER HAVE DECIDED NOT TO STAND AGAIN FOR RE-ELECTION TO BOARD OF DIRECTORS AT NEXT AGM.  Full Article